Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes

Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes

Insulinemia [ Time Frame: Plasma insulin concentration in mUI/mL, measured at fasting, during a 2 hour OGTT and after ]
Plasma insulin concentration in mUI/mL measured before and 30, 60, 90 and 120 min after an oral glucose tolerance test (OGTT, 75g glucose).

Mean interstitial glucose concentration [ Time Frame: Before and after 1 month and 3 months of intervention ]
Mean interstitial glucose concentration measured continuously by a glucose monitor placed on the tricep for 24hours for 10 days.

Daily glycemia variability [ Time Frame: Before and after 1 month and 3 months of intervention ]
Standard deviation (SD) of interstitial glucose concentration measured continuously by a glucose monitor placed on the tricep 24hours throughout 10 days.

Fasting A1c concentration [ Time Frame: Time Frame: Before and after 1 month and 3 months of intervention ]
Fasting A1c concentration expressed in %

Fasting fructosamine concentration [ Time Frame: Before and after 1 month and 3 months of intervention ]
Fasting fructosamine concentration in umol/L

12-hour exogenous glucose oxidation [ Time Frame: Before and after 1 month of intervention ]
Rates of 13C recovery (% of the dose) in expired CO2 following the ingestion of U-13C-glucose in both breakfast and lunch meals.

12-hour endogenous glucose oxidation [ Time Frame: Before and after 1 month of intervention ]
Rates of D2 recovery (% of the dose) in expired urines following the infusion of (2,2H2) glucose.

12 hour CO2 production [ Time Frame: Before and after 1 month of intervention ]
CO2 production measured by indirect calorimetry (ParvoMedics TrueOne 2400, Salt Lake City) for 20 minutes every hour from 0800h to 1800h.

12 hour O2 production [ Time Frame: Before and after 1 month of intervention ]
O2 production measured by indirect calorimetry (ParvoMedics TrueOne 2400, Salt Lake City) for 20 minutes every hour from 0800h to 1800h.

12 Urine excretion [ Time Frame: Before and after 1 month of intervention ]
Urine will be measured every hour from 0730h to 1830h

Glucose kinetics [ Time Frame: Before and after 1 month of intervention ]
Steele’s equation for non-steady-state will be used to compute RaT and RaE, as well as the rates of disappearance (RdT and RdE) from the percentage of [6,6-2H2]glucose6 and of 13C-glucose in plasma glucose61. EGP will be computed as RaT-RaE. Nonoxidative glucose disposal (NOGD) will be calculated by subtracting total carbohydrate oxidation from (RdT + RdE). Plasma glucose utilization will be assumed to be equivalent to RdT as has been confirmed previously. Muscle glycogen utilization during the active period will be calculated as total carbohydrate utilization during exercise minus plasma glucose utilization during exercise.

Fasting and postprandial glucose [ Time Frame: Before and after 1 month of intervention ]
Fasting and postprandial glucose in mg/dl measured in response to standard lunch

Fasting and postprandial insulin [ Time Frame: Before and after 1 month of intervention ]
Fasting and postprandial insulin in ml/iu measured in response to standard lunch

Fasting and postprandial C-Peptide [ Time Frame: Before and after 1 month of intervention ]
Fasting and postprandial C-peptide nmol/mL measured in response to standard lunch

Fasting and postprandial glucagon [ Time Frame: Before and after 1 month of intervention ]
Fasting and postprandial glucagon in pg/mL measured in response to standard lunch

Fasting and postprandial catecholamines [ Time Frame: Before and after 1 month of intervention ]
Fasting and postprandial catecholamines in pg/mL measured in response to standard lunch

Skeletal muscle content of protein kinase B (Akt) (Aktser473/total) [ Time Frame: Before and after 1 month of intervention ]
Vastus lateralis skeletal muscle biopsies will be collected from fasting participants by the Bergstrom technique. Biopsies will be used to measure protein kinase B (Akt) (Aktser473/total) using western blotting.

Skeletal muscle content of ACC (ACCS79/ total) [ Time Frame: Before and after 1 month of intervention ]
Vastus lateralis skeletal muscle biopsies will be collected from fasting participants by the Bergstrom technique. Biopsies will be used to measure ACC (ACCS79/ total) using western blotting.

Skeletal muscle content of TBC1D4 (AS160/ total) [ Time Frame: Before and after 1 month of intervention ]
Vastus lateralis skeletal muscle biopsies will be collected from fasting participants by the Bergstrom technique. Biopsies will be used to measure TBC1D4 (AS160/ total) using western blotting.

Skeletal muscle content of COX4 [ Time Frame: Before and after 1 month of intervention ]
Vastus lateralis skeletal muscle biopsies will be collected from fasting participants by the Bergstrom technique. Biopsies will be used to measure COX4 using western blotting.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 12, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments